文献速递淋巴瘤造血干细胞移植与细胞治疗

MATRix方案继以自体移植治疗原发性中枢神经系统淋巴瘤的长期疗效、安全性与神经耐受性:IELSG32随机试验7年结果

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
PubMed 文献 · Leukemia · 2022-05-13

IELSG32随机试验纳入219例≤70岁HIV阴性原发性中枢神经系统淋巴瘤患者,随机接受甲氨蝶呤-阿糖胞苷(A组)、加用利妥昔单抗(B组)或MATRix方案(C组),缓解或稳定者二次随机接受全脑放疗或卡莫司汀-塞替派预处理自体移植。中位随访88个月显示MATRix组7年总生存率56%,MATRix联合巩固治疗达70%。

要点

  • MATRix组7年总生存率为56%,A组21%、B组37%,B组优于A组提示加用利妥昔单抗获益。
  • 全脑放疗与自体移植疗效相当,MATRix联合巩固治疗7年总生存率达70%。
  • 挽救治疗无效,仅晚期复发后再次接受甲氨蝶呤治疗者获益。

核心结论

  • MATRix方案带来持久优异结局,7年总生存率A组21%、B组37%、C组56%,MATRix联合巩固治疗达70%。
  • B组优于A组提示加用利妥昔单抗有获益;全脑放疗与自体移植疗效相当得到证实。
  • 挽救治疗无效,仅晚期复发后再次接受甲氨蝶呤治疗者记录到获益。
  • MATRix和自体移植未导致更高的非复发死亡率或第二肿瘤发生率。

研究设计与样本

  • IELSG32随机试验纳入219例≤70岁HIV阴性原发性中枢神经系统淋巴瘤患者。
  • 患者随机接受甲氨蝶呤-阿糖胞苷(A组)、甲氨蝶呤-阿糖胞苷-利妥昔单抗(B组)或甲氨蝶呤-阿糖胞苷-塞替派-利妥昔单抗(MATRix;C组)。
  • 缓解或疾病稳定者二次随机接受全脑放疗或卡莫司汀-塞替派预处理自体移植。
  • 本次报告中位随访88个月。

主要发现

  • 7年总生存率A组21%、B组37%、C组56%。
  • 接受MATRix联合巩固治疗的患者7年总生存率为70%。
  • 8例(4%)患者发生第二肿瘤。
  • 接受全脑放疗的患者注意力和执行功能受损,而接受自体移植的患者这些功能以及记忆和生活质量改善。

局限性

  • 原文指出需更长随访以可靠评估总生存、挽救治疗疗效、晚期并发症、第二肿瘤和认知障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or methotrexate-cytarabine-thiotepa-rituximab (MATRix; arm C). A second randomization allocated patients with responsive/stable disease to whole-brain irradiation (WBRT) or carmustine-thiotepa-conditioned autologous transplantation (ASCT). First results, after a median follow-up of 30 months, showed that MATRix significantly improves outcome, with both WBRT and ASCT being similarly effective. However, sound assessment of overall survival (OS), efficacy of salvage therapy, late complications, secondary tumors, and cognitive impairment requires longer follow-up. Herein, we report the results of this trial at a median follow-up of 88 months. As main findings, MATRix was associated with excellent long-lasting outcome, with a 7-year OS of 21%, 37%, and 56% respectively for arms A, B, and C. Notably, patients treated with MATRix and consolidation had a 7-year OS of 70%. The superiority of arm B on arm A suggests a benefit from the addition of rituximab. Comparable efficacy of WBRT and ASCT was confirmed. Salvage therapy was ineffective; benefit was recorded only in patients with late relapse re-treated with methotrexate. Eight (4%) patients developed a second cancer. Importantly, MATRix and ASCT did not result in higher non-relapse mortality or second tumors incidence. Patients who received WBRT experienced impairment in attentiveness and executive functions, whereas patients undergoing ASCT experienced improvement in these functions as well as in memory and quality of life.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022. PMID: 35562406. doi:10.1038/s41375-022-01582-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。